Alemtuzumab: A new therapy for active relapsing-remitting multiple sclerosis

Multiple Sclerosis Journal

Volumn 21, Issue 1, 2015, Pages 22-34

  Hartung, Hans Peter ^a   Aktas, Orhan ^a   Boyko, Alexey N ^b  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b Moscow City Multiple Sclerosis Center   (Russian Federation)

Author keywords

Alemtuzumab; CD52; monoclonal antibody; multiple sclerosis

Indexed keywords

ALEMTUZUMAB; BETA1A INTERFERON; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY;

AUTOIMMUNE DISEASE; BRADYCARDIA; BRONCHITIS; DISABILITY; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; ESOPHAGUS CANDIDIASIS; FEVER; FOLLOW UP; GOODPASTURE SYNDROME; HEADACHE; HEART PALPITATION; HERPES ZOSTER; HERPETIC STOMATITIS; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; IDIOPATHIC THROMBOCYTOPENIC PURPURA; INFECTION; INFLUENZA; INFUSION RELATED REACTION; LYMPHOCYTE DEPLETION; LYMPHOCYTOPENIA; MULTIPLE SCLEROSIS; MYCOSIS; NAUSEA; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RECURRENCE RISK; REVIEW; RHINOPHARYNGITIS; SINUSITIS; TACHYCARDIA; THYROID DISEASE; TUBERCULOSIS; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; ARTICLE; BREAST DISEASE; CLINICAL PRACTICE; CONNECTIVE TISSUE DISEASE; DISEASE FREE SURVIVAL; EAR DISEASE; ENDOCRINE DISEASE; EYE DISEASE; GASTROINTESTINAL DISEASE; HEART DISEASE; HEMATOLOGIC DISEASE; HEPATOBILIARY DISEASE; IMMUNOPATHOLOGY; INFESTATION; INJECTION SITE REACTION; INJURY; INNER EAR DISEASE; INTOXICATION; KIDNEY DISEASE; LYMPHATIC SYSTEM DISEASE; MEDIASTINUM DISEASE; MENTAL DISEASE; MUSCULOSKELETAL DISEASE; NEUROLOGIC DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; RESPIRATORY TRACT DISEASE; RISK MANAGEMENT; SKIN DISEASE; THORAX DISEASE; TREATMENT OUTCOME; URINARY TRACT DISEASE; VASCULAR DISEASE; META ANALYSIS; MULTIPLE SCLEROSIS, RELAPSING-REMITTING;

ANTIBODIES, MONOCLONAL, HUMANIZED; HUMANS; IMMUNOLOGIC FACTORS; MULTIPLE SCLEROSIS, RELAPSING-REMITTING;

EID: 84922924306     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458514549398     Document Type: Review

References (35)

1. Nylander A and Hafler DA. Multiple sclerosis. J Clin Invest 2012; 122: 1180-1188.
2. Hauser SL, Chan JR and Oksenberg JR. Multiple sclerosis: Prospects and promise. Ann Neurol 2013; 74: 317-327.
3. Hu Y, Turner MJ, Shields J, et al. Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model. Immunology 2009; 128: 260-270.
4. Krumbholz M, Derfuss T, Hohlfeld R, et al. B cells and antibodies in multiple sclerosis pathogenesis and therapy. Nat Rev Neurol 2012; 8: 613-623.
5. Havari E, Turner MJ, Campos-Rivera J, et al. Impact of alemtuzumab treatment on the survival and function of human regulatory T cells in vitro. Immunology 2013; 141: 123-131.
6. Cox AL, Thompson SA, Jones JL, et al. Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis. Eur J Immunol 2005; 35: 3332-3342.
7. Cohen JA, Coles AJ, Arnold DL, et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: A randomised controlled phase 3 trial. Lancet 2012; 380: 1819-1828.
8. Coles AJ, Twyman CL, Arnold DL, et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: A randomised controlled phase 3 trial. Lancet 2012; 380: 1829-1839.
9. Genzyme Therapeutics Ltd. Lemtrada™ (alemtuzumab 12 mg concentrate for solution for infusion). EU summary of product characteristics, http://www.ema.europa.eu/docs/en-GB/document- library/EPAR-Product-Information/human/003718/ WC500150521.pdf (2013, accessed 20 January 2014).
10. CAMMS Trial Investigators, Coles AJ, Compston DA, et al.Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med 2008; 359: 1786- 1801.
11. Coles AJ, Fox E, Vladic A, et al. Alemtuzumab more effective than interferon beta-1a at 5-year follow-up of CAMMS223 clinical trial. Neurology 2012; 78: 1069-1078.
12. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet 1998; 352: 1498-1504.
13. Hartung HP and Aktas O. Evolution of multiple sclerosis treatment: Next generation therapies meet next generation efficacy criteria. Lancet Neurol 2011; 10: 293-295.
14. Coles AJ, Fox E, Vladic A, et al. Alemtuzumab versus interferon beta-1a in early relapsing-remitting multiple sclerosis: Post-hoc and subset analyses of clinical efficacy outcomes. Lancet Neurol 2011; 10: 338-348.
15. Freedman MS, Kaplan JM and Markovic-Plese S. Insights into the mechanisms of the therapeutic efficacy of alemtuzumab in multiple sclerosis. J Clin Cell Immunol 2013; 4: 1000152.
16. Turner MJ, LaMorte MJ, Chretien N, et al. Immune status following alemtuzumab treatment in human CD52 transgenic mice. J Neuroimmunol 2013; 261: 29-36.
17. Rao SP, Sancho J, Campos-Rivera J, et al. Human peripheral blood mononuclear cells exhibit heterogeneous CD52 expression levels and show differential sensitivity to alemtuzumab mediated cytolysis. PLoS One 2012; 7: e39416.
18. Jones JL, Anderson JM, Phuah CL, et al. Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity. Brain 2010; 133: 2232-2247.
19. Zhang X, Tao Y, Chopra M, et al. Differential reconstitution of T cell subsets following immunodepleting treatment with alemtuzumab (antihuman CD52 monoclonal antibody) in patients with relapsing-remitting multiple sclerosis. J Immunol 2013; 191: 5867-5874.
20. Kovarova I, Arnold DL, Cohen J, et al. Alemtuzumab pharmacokinetics and pharmacodynamics in Comparison of Alemtuzumab and Rebif Efficacy in Multiple Sclerosis (CARE-MS I). European Neurological Society 22nd Meeting, 9-12 June 2012, Prague, Czech Republic, Poster P341.
21. Fernandez O, Arnold DL, Cohen J, et al. Alemtuzumab improves disability by month 6 independent of relapse history in relapsing-remitting multiple sclerosis patients: CARE-MS II. European Neurological Society 23rd Meeting, 8-11 June 2013, Barcelona, Spain.
22. McCarthy CL, Tuohy O, Compston DAS, et al. Immune competence after alemtuzumab treatment of multiple sclerosis. Neurology 2013; 81: 872-876.
23. Wray S, Arnold DL, Johen J, et al. Herpes infection risk reduced with acyclovir prophylaxis after alemtuzumab. Consortium of Multiple Sclerosis Centers 2013 Annual Meeting, 29 May-1 June 2013, Orlando, FL, USA, Poster DX60.
24. Jones JL, Thompson SA, Loh P, et al. Human autoimmunity after lymphocyte depletion is caused by homeostatic T-cell proliferation. Proc Natl Acad Sci U S A 2013; 110: 20200-20205.
25. Krupica T, Fry TJ and Mackall CL. Autoimmunity during lymphopenia: A two-hit model. Clin Immunol 2006; 120: 121-128.
26. Daniels GH, Vladic A, Brinar V, et al. Alemtuzumabrelated thyroid dysfunction in a phase 2 trial of patients with relapsing-remitting multiple sclerosis. J Clin Endocrinol Metab 2013; 99: 80-89.
27. Miller T. Detection, incidence, and management of thyroid autoimmunity in Comparison of Alemtuzumab and Rebif in Multiple Sclerosis (CARE-MS) I and II. 65th Annual Meeting of the American Academy of Neurology (AAN). 16-23 March 2013, San Diego, CA, USA, P01.173.
28. Cuker A, Coles AJ, Sullivan H, et al. A distinctive form of immune thrombocytopenia in a phase 2 study of alemtuzumab for the treatment of relapsing- remitting multiple sclerosis. Blood 2011; 118: 6299-6305.
29. Clatworthy MR, Wallin EF and Jayne DR. Antiglomerular basement membrane disease after alemtuzumab. N Engl J Med 2008; 359: 768-769.
30. Wynn D, Arnold DL, Cohen JA, et al. Detection, incidence, and management of glomerulonephritis in the alemtuzuamb clinical development program. European Committee for Treatment & Research in Multiple Sclerosis 29th Congress, 2-5 October 2013, Copenhagen, Denmark Poster P597.
31. Meyer D, Coles A, Oyuela P, et al. Case report of anti-glomerular basement membrane disease following alemtuzumab treatment of relapsing-remitting multiple sclerosis. Mult Scler Relat Disord 2013; 2: 60-63.
32. Tuohy O, Costelloe L, Hill-Cawthorne G, et al. Alemtuzumab treatment of multiple sclerosis: Long-term safety and efficacy. J Neurol Neurosurg Psychiatry. Epub ahead of print 21 May 2014. DOI: 10.1136/jnnp-2014-307721.
33. Azzopardi L, Thompson SAJ, Harding KE, et al. Predicting autoimmunity after alemtuzumab treatment of multiple sclerosis. J Neurol Neurosurg Psychiatry 2014; 85: 795-798.
34. Clanet MC, Wolinsky JS, Ashton RJ, et al. Risk evaluation and monitoring in multiple sclerosis therapeutics. Mult Scler. Epub ahead of print 30 November 2013. 2014; 20: 1306-1311. DOI: 10.1177/1352458513513207.
35. Kousin-Ezewu O, Azzopardi L, Parker RA, et al. Accelerated lymphocyte recovery after alemtuzumab does not predict multiple sclerosis activity. Neurology 2014; 82: 2158-2164.